Annovis Bio Inc (ANVS NYSE) stock market data APIs
$2.4854
-0.1(-4%)
as of September 12, 2025
Try our APIs with
free plan!
Annovis Bio Inc Financial Data Overview
Price chart is built with
Anychart
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Prev. Close
2.4854
Open
2.388
High
2.5407
Low
2.3564
52 wk Range
1.11-10.54
Market Cap
48 326 K
Shares Outstanding
19 486 K
EPS
-0.32
Beta
1.642
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Annovis Bio Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Annovis Bio Inc data using free add-ons & libraries
Get Annovis Bio Inc Fundamental Data
Annovis Bio Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.4031
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Annovis Bio Inc News
New
Annovis Bio appoints CEO as acting CFO following executive resignation
Annovis Bio, Inc. (NYSE:ANVS) announced the upcoming resignation of Andrew Walsh, Vice President of Finance and Principal Financial Officer, effective August 22. According to a company statement based...
Annovis Bio (NYSE:ANVS) Reports Narrower Q2 2025 Loss, Advances Alzheimer's and Parkinson's Trials
Annovis Bio Inc. (NYSE:ANVS [https://www.chartmill.com/stock/quote/ANVS]) reported its second-quarter 2025 financial results, posting a net loss per share of $0.32, which was narrower than the analyst...
Annovis Bio GAAP EPS of -$0.32 beats by $0.08
* Annovis Bio press release [https://seekingalpha.com/pr/20198633-annovis-provides-corporate-updates-and-reports-second-quarter-2025-financial-results] (NYSE:ANVS [https://seekingalpha.com/symbol/AN...
Annovis Bio receives NYSE approval for compliance plan
* Annovis Bio (NYSE:ANVS [https://seekingalpha.com/symbol/ANVS]) received NYSE acceptance of its compliance plan regarding minimum market capitalization and stockholders' equity. * The company has...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
